RJA
SNDX icon

Raymond James & Associates’s Syndax Pharmaceuticals SNDX Stock Holding History

Raymond James & Associates’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-15,000
Closed -$112K – 3748
2019
Q3 		$112K Hold
15,000
– – ﹤0.01% 3375
2019
Q2 		$140K Sell
15,000
-5,000
-25% -$36.4K ﹤0.01% 3350
2019
Q1 		$105K Sell
20,000
-2,000
-9% -$11.4K ﹤0.01% 3380
2018
Q4 		$98K Buy
+22,000
New +$121K ﹤0.01% 3308

Other funds holding SNDX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Raymond James & Associates's SNDX Position: Q4 2019 in Review

Raymond James & Associates sold out of Syndax Pharmaceuticals (SNDX) in Q4 2019, closing a stake of 15,000 shares — an estimated $112K sold.

Raymond James & Associates first reported a position in SNDX in Q4 2018 and held it in 4 quarters. The position peaked at $140K in Q2 2019. 72 funds tracked by Wall St. Rank hold SNDX as of Q4 2019.

  • Raymond James & Associates reported no remaining Syndax Pharmaceuticals position as of Q4 2019 after selling out during the quarter.
  • Raymond James & Associates sold 15,000 Syndax Pharmaceuticals shares in Q4 2019, an estimated $112K.
  • Raymond James & Associates first reported a position in Syndax Pharmaceuticals in Q4 2018 and held it in 4 quarters.
  • Raymond James & Associates's Syndax Pharmaceuticals position peaked at $140K in Q2 2019.
  • 72 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q4 2019.

Based on Raymond James & Associates's 13F filing for Q4 2019, filed 12 Feb 2020.